FAQs
Check out some of the most frequently asked questions about the industry and our solutions.
FAQs
Check out some of the most frequently asked questions about the industry and our solutions.
FAQs
Check out some of the most frequently asked questions about the industry and our solutions.
INDUSTRY
The probability of technical and regulatory success, abbreviated as PTRS, is also often referred to as the probability of success or likelihood of approval. It indicates the probability that a drug will move from one phase to the next and if the drug will receive the ultimate goal of FDA approval. It demonstrates the expected chance of regulatory approval. PTRS assessments can change over time as new data emerges, such as readouts from competitors, clinical trial results, etc.
The probability of success in drug development is often used interchangeably with PTRS. Likelihood of approval (LoA) is another term that essentially means the same as PTRS and PoS. In short, it’s a simple way to describe the chances of receiving FDA approval.
New product planning in the pharma industry brings the commercial viewpoint into R&D pipeline programs to increase the probability of success, particularly from the commercial lens.
In short, far too long. The full timeline varies and ranges from 10-15 years (PhRMA). According to a report from the Biotechnology Innovation Organization (BIO), it takes 10.5 years to go from Phase 1 to regulatory approval.
Too much. According to a Deloitte report, developing a new asset costs an average of $2.2B.
Not enough. According to the PhRMA website, only 12% of new molecular entities that enter clinical trials eventually receive FDA approval. There are various facts and figures out there based on the data used for the calculation, the indication, and the development phase being evaluated. For instance, between 2016 and 2020, the average industry success rates for Phase II and Phase III were 29–34% and 70–73%, respectively.
INTELLIGENCIA AI SOLUTIONS
Our suite of solutions includes our SaaS-based tool, Portfolio Optimizer, along with Clinical Development Insights, data as a subscription service and custom insights. Visit our solutions page to learn more.
We curate and harmonize over 1.5B data points that capture both clinical and biological data such as science-drug biology; indications; regulatory designations; patents/funding; genes, proteins, targets, and gene expression; biological pathways; clinical trial design, setup, execution and outcomes, to name a handful. This is supported by a comprehensive data strategy, automation and technology, and expert data curation to create a centralized data repository. If you have specific questions about our process and the data we capture, let’s talk.
Carnegie Mellon University shared an excellent description of explainable artificial intelligence with the following: Explainable artificial intelligence (XAI) is a powerful tool for answering critical How? and Why? questions about AI systems and can be used to address rising ethical and legal concerns. As a result, AI researchers have identified XAI as a necessary feature of trustworthy AI, and explainability has experienced a recent surge in attention.
Within Portfolio Optimizer, our Explainable AI feature visually shows the drivers behind the why of the PTRS prediction to eliminate the mysterious AI black box and give you confidence in our PTRS assessments.
New data is ingested daily with weekly and regular core AI algorithm updates.
Absolutely! This is one of the many ways in which the data behind our software solution can be leveraged and manipulated for your specific needs. We also offer a data-as-a-subscription service (DaaS).
You can. Contact us to learn more.
Our PTRS assessments boast an 80% prospective and 91% retrospective accuracy* regarding the predictive accuracy of forecasting asset success (FDA approval). To better understand our methodology, reach out, and we’d be happy to share more.
*Data as of February 2024.
COMPANY
The company was co-founded in 2017 in New York. Read more about our company story and leadership.
Intelligencia AI is headquartered in New York, with offices in San Francisco and Athens, Greece, and a global employee presence.
Intelligencia AI primarily works with mid-large pharmaceutical organizations, contract research organizations (CROs), consultancies, and financial markets such as banks and hedge funds.
Please visit our careers page and check back often, as we’re growing and always looking for new talent.